S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients|
|Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting|
|A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History (2014/10/22)|
|Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference|
|Regulus Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call|
|Regulus Announces Commencement of Public Offering of Common Stock|
|Regulus Reports Third Quarter 2014 Financial Results and Recent Highlights|
|Regulus Announces Notice of Allowance from U.S. Patent Office Related to microRNA-103/107 Program in Metabolic Disorders|
|Regulus Presents New Preclinical Data on Multiple Programs and Provides Portfolio Overview at 10th Annual Oligonucleotide Therapeutics Society (OTS) Meeting|
|Regulus to Present at the Credit Suisse Healthcare Conference|
Click above to view more mutual fund data and stats for rgls - Regulus Therapeutics Inc.